ECKERT & ZIEGLER BG 
By Seneffe, Belgium, November 4, 2013, Eckert & Ziegler BEBIG announces to have received an order for the delivery of their state-of-the art MultiSource® afterloaders for HDR brachytherapy representing one of the largest single orders ever received by the company.
The decision in favour of MultiSource® was driven by the systems unique miniaturized cobalt-60 source as well as exclusive safety features enabling for a high level of accuracy. "Due to its technical characteristics and the long half-life of the isotope used, our afterloader is ideal for the region. The radiation source only needs to be replaced every five years," said Abel Luzuriaga, Managing Director of Eckert & Ziegler BEBIG.
A part of the ordered devices will already be delivered within the next month while the remaining afterloaders are expected in Bangladesh in the first quarter of 2014. The deal has a total value of around 3.1 million ? and was initiated by Eckert & Ziegler BEBIG India.
"We are pleased to see that emerging countries in Asia, Africa and South America are increasingly gaining access to the latest medical infrastructure that has long been available in other parts of the world. Our range of MultiSource® devices with their distinguished characteristics is exactly what decision-makers are looking for," Abel Luzuriaga added.
The tender was advertised in the context of the "Health, Population & Nutrition Sector Development Program (HPNSDP)". Amongst others, the five year program aims to enhance the cancer treatment in The People's Republic of Bangladesh that is facing rising incidences of the disease. It is the third sector-wide program of its kind in the country. Supported by the European Union, the World Bank, UNICEF, the World Health Organization (WHO) and 17 more development partners, the program will end in June 2016.
For more information regarding the MultiSource® system, please see http://www.bebig.eu/home/products/hdr-brachytherapy.html:
http://www.bebig.eu/home/products/hdr-brachytherapy.html
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.
Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe, in India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists, and medical physicists. Eckert & Ziegler BEBIG employs 190 people.
The company has been listed on the Euronext stock exchange since April 1997.
Contact:
Claudia Wolf, Head of Marketing, Tel: +49 30 94 10 84 272, marketing@bebig.eu:
https://mce_host/hugin/marketing@bebig.eu
Karolin Riehle, Investor Relations, Tel. + Tel.: +32 (0) 64 520 808, ir@bebig.eu:
https://mce_host/hugin/ir@bebig.eu
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
